Phase II trial of Zimberelimab, a PD-1 inhibitor, in advanced NSCLC immunotherapy combinations.

This open-label platform study evaluates objective response and safety of various immunotherapy regimens in advanced non-small cell lung cancer. Investigational arms pair zimberelimab (a PD-1 inhibitor) with domvanalimab (a TIGIT antibody) or quemliclustat (a CD73 adenosine inhibitor), administered alone or with platinum doublet chemotherapy or docetaxel (a tubulin inhibitor). Sponsored by Gilead Sciences, the trial is conducted at 50+ sites.